VX-745 clinical trials
Also written VX-745 and Neflamapimod.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses VX-745 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 10
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
EIP Pharma Inc (9) · University Hospital, Toulouse (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses VX-745 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokeCompletedPhase 2EIP Pharma IncNCT06987643Written as Neflamapimod
- RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesCompletedPhase 2EIP Pharma IncNCT05869669Written as Neflamapimod
- A Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesCompletedPhase 2EIP Pharma IncNCT06815965Written as neflamapimod
- Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaActive, not recruitingPhase 2EIP Pharma IncNCT07033481Written as Neflamapimod
- Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy BodiesCompletedPhase 2EIP Pharma IncNCT04001517Written as Neflamapimod
- Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease PatientsCompletedPhase 2University Hospital, ToulouseNCT03435861Written as VX-745
- Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington DiseaseTerminatedPhase 2EIP Pharma IncNCT03980938Written as neflamapimod
- Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's DiseaseCompletedPhase 2EIP Pharma IncNCT03402659Written as neflamapimod
- A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)CompletedPhase 2EIP Pharma IncNCT02423122Written as VX-745
- Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild ADCompletedPhase 2EIP Pharma IncNCT02423200Written as VX-745
Codes
What other systems call VX-745 · ClinicalTrials.gg INT004474
- MeSH (NLM) C464966VX-745Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) TYL52QM320NEFLAMAPIMODConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C464966 | VX-745 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TYL52QM320 | NEFLAMAPIMOD | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.